APVO - CIK 0001671584
The table below shows Aptevo Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.96M | -$6.58M | -$6.65M | $4.57M | -$5.12M | -$7.50M |
| Capital expenditure | - | - | - | - | - | $191.00K |
| Investing cash flow | $0.00 | $0.00 | - | - | - | -$191.00K |
| Dividends paid | - | - | - | - | - |
Aptevo Therapeutics Inc. reported operating cash flow of -$25.59M for fiscal year 2025. That is down 7.6% from -$23.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$41.57M (FY 2017) to -$25.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $871.00K | $0.00 | -$3.00K | -$1.87M | -$4.94M | $23.94M |